VCP
ABUS icon

Verus Capital Partners’s Arbutus Biopharma ABUS Stock Holding History

Verus Capital Partners’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.2K Hold
15,250
– – ﹤0.01% 494
2026
Q1 		$68.6K Sell
15,250
-1,400
-8% -$6.12K ﹤0.01% 464
2025
Q4 		$80.1K Hold
16,650
– – 0.01% 443
2025
Q3 		$75.6K Buy
16,650
+50
+0.3% +$184 0.01% 415
2025
Q2 		$51.3K Sell
16,600
-200
-1% -$664 ﹤0.01% 371
2025
Q1 		$58.6K Sell
16,800
-2,550
-13% -$8.5K 0.01% 374
2024
Q4 		$63.3K Sell
19,350
-7,550
-28% -$27.8K 0.01% 360
2024
Q3 		$104K Sell
26,900
-14,635
-35% -$56.1K 0.01% 351
2024
Q2 		$128K Sell
41,535
-400
-1% -$1.2K 0.01% 338
2024
Q1 		$108K Buy
41,935
+9,800
+30% +$25.4K 0.01% 347
2023
Q4 		$80.3K Sell
32,135
-1,000
-3% -$1.96K 0.01% 317
2023
Q3 		$67.3K Sell
33,135
-500
-1% -$1.05K 0.01% 300
2023
Q2 		$77.4K Sell
33,635
-1,000
-3% -$2.6K 0.01% 288
2023
Q1 		$105K Buy
34,635
+7,310
+27% +$20.6K 0.02% 281
2022
Q4 		$63.7K Sell
27,325
-375
-1% -$897 0.01% 261
2022
Q3 		$53K Buy
+27,700
New +$65.2K 0.01% 268
2022
Q2 		– Sell
-28,600
Closed -$72K – 289
2022
Q1 		$72K Buy
+28,600
New +$87.5K 0.01% 318

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Verus Capital Partners's ABUS Position: Q2 2026 in Review

Verus Capital Partners held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 15,250 shares worth $73.2K. The position accounts for ﹤0.01% of the portfolio, ranked #494.

Verus Capital Partners first reported a position in ABUS in Q1 2022 and has held it in 17 quarters since. The position peaked at $128K in Q2 2024. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Verus Capital Partners held 15,250 shares of Arbutus Biopharma worth $73.2K as of Q2 2026.
  • Verus Capital Partners left its Arbutus Biopharma share count unchanged in Q2 2026.
  • Arbutus Biopharma made up ﹤0.01% of Verus Capital Partners's portfolio in Q2 2026, its #494 holding.
  • Verus Capital Partners first reported a position in Arbutus Biopharma in Q1 2022 and has held it in 17 quarters since.
  • Verus Capital Partners's Arbutus Biopharma position peaked at $128K in Q2 2024.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Verus Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.